The Mortgage Bankers Association (MBA) released its weekly report on mortgage applications Wednesday morning, noting a decrease of 0.5% in the group’s seasonally adjusted composite index for the week ending June 29. Mortgage loan rate movements were mixed last week.
Famed investor andBerkshire Hathaway(NYSE: BRK-A) (NYSE: BRK-B) CEO Warren Buffett is known for preferring value stocks and dividend stocks. He has seen success with both by investing in undervalued companies and by buying dividend-paying stocks that help fill his coffers, funding acquisitions and further stock purchases.
There is a clear overlap between the value stock and dividend stock....More>>>
Century Casinos (NASDAQ: CNTY) is one of 31 public companies in the “Hotels & motels” industry, but how does it compare to its competitors? We will compare Century Casinos to similar companies based on the strength of its analyst recommendations, institutional ownership, valuation, earnings, risk, profitability and dividends.
AES Corp (NYSE:AES) announced a quarterly dividend on Friday, April 13th, RTT News reports. Investors of record on Tuesday, May 1st will be paid a dividend of 0.13 per share by the utilities provider on Tuesday, May 15th. This represents a $0.52 dividend on an annualized basis and a yield of 4.59%.
AES has increased its dividend payment by an average of 33.9% annually over the last three....More>>>
Nektar Therapeutics (NASDAQ:NKTR) is an intriguing commercial-stage biotech company that’s just reported positive late-stage trial results for its pain-busting drug NKTR-181. However, shares have jumped on the news, and the company’s market cap has swollen to more than $3 billion. Is there more running room left for its investors?
Things are moving fast in renewable energy. Really fast. Consider that in 2008 wind farms supplied just 1.5% of all electricity in the United States. But by 2019 wind power is expected to contribute 6.9% of American electricity and overtake hydropower as the top renewable energy source.
The rise of wind power wouldn’t have been possible without two companies in particular, which combine....More>>>
So much for the 70 million iPhones analysts think Apple Inc. (NASDAQ: AAPL) will buy between now and year end. At least that is the conclusion which can be drawn from a recent tweet from Survey Monkey:
How likely are consumers to buy #iPhone7? Only 5% say they’re extremely likely #mondaymotivation #mobilemonday #tech svy.mk/2cL40Cr
Apple’s share price has soared based on....More>>>
President and CEO of Tallgrass Energy Gp Lp (NYSE:TEGP) David G Jr Dehaemers bought 5,428 shares of TEGP on 11/09/2017 at an average price of $25.04 a share. The total cost of this purchase was $135,917.
Tallgrass Energy GP LP owns, operates, acquires and develops midstream energy assets in North America. The company provides crude oil transportation to customers in Wyoming, Colorado, and....More>>>
SOFIA, Bulgaria The European Union has called on U.S. President Donald Trump's administration to stop threating it with tariffs on steel and aluminum, saying Thursday it is prepared to discuss trade but not at gun-point.
In March, Trump slapped tariffs of 25% on steel imports and 10% on impo
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it under the microscope...
Editor's note: Seeking Alpha is proud to welcome Michael McGrath as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more 禄
If you're not familiar with how Social Security works, you might assume that there's a single age at which eligible recipients have to file for benefits. Not so. You actually get an eight-year window to claim benefits that begins at age 62 and carries through until age 70. (Technically, you're no
The biopharma and drug supply chain sectors outperformed the market last week, even as Trump administration officials pressed the president's blueprint to lower drug prices, with tough rhetoric for drugmakers and public shaming of pharmaceutical firms for supposedly blocking competition.